Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
17.24
-0.42 (-2.35%)
At close: Apr 4, 2025, 4:00 PM
17.01
-0.23 (-1.31%)
After-hours: Apr 4, 2025, 7:58 PM EDT
Rigel Pharmaceuticals Employees
As of December 31, 2024, Rigel Pharmaceuticals had 164 total employees, including 162 full-time and 2 part-time employees. The number of employees increased by 17 or 11.56% compared to the previous year.
Employees
164
Change (1Y)
17
Growth (1Y)
11.56%
Revenue / Employee
$1,093,159
Profits / Employee
$106,616
Market Cap
307.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RIGL News
- 2 days ago - Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability - Seeking Alpha
- 2 days ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 10 days ago - Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PRNewsWire
- 27 days ago - Rigel Appoints Mark W. Frohlich, M.D. - PRNewsWire
- 4 weeks ago - Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - PRNewsWire